LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring

The pharmacokinetic profiling of drug substances and corresponding metabolites in the biological matrix is one
of the most informative tools for the treatment efficacy assessment. Therefore, to satisfy the need for comprehensive
monitoring of anti-tuberculosis drugs in human plasma, a liquid chromatography-tandem mass spectrometry
(LC-MS/MS) method was developed and validated for simultaneous quantification of first-line antituberculosis
drugs (ethambutol, isoniazid, pyrazinamide, and rifampicin) along with their six primary metabolites.
Simple single-step protein precipitation with methanol was chosen as the most convenient sample pretreatment
method. Chromatographic separation of the ten analyte mixture was achieved within 10 minutes on
a reverse-phase C8 column using mobile phase gradient mode. The multiple reaction monitoring mode (MRM)
was used for analyte detection and quantification in patient samples. The chosen quantification ranges fully
covered expected plasma concentrations. The method exhibited acceptable selectivity; the within- and betweenrun
accuracy ranged from 87.2 to 113.6%, but within- and between-run precision was between 1.6 and 14.9% (at
the LLOQ level CV < 20%). Although the response of the isonicotinic acid varied depending on the matrix source
(CV 21.8%), validation results proved that such inconsistency does not affect the accuracy and precision of results.
If stored at room temperature plasma samples should be processed within 4 h after collection, temporary
storage at 􀀀 20 ◦C up to 24 h is acceptable due to stability issues of analytes. The developed method was applied
for the patient sample analysis (n = 34) receiving anti-tuberculosis treatment with the first-line drugs.